Unigen, Estée Lauder sign product license and supply agreement

Unigen, Estée Lauder sign product license and supply agreement

Unigen Inc. announced that it has entered into an exclusive product license and supply agreement with a subsidiary of The Estée Lauder Companies Inc.

Unigen Inc., announced that it has entered into an exclusive product license and supply agreement with a subsidiary of The Estée Lauder Companies Inc. (NYSE EL), relating to the development and commercialization of Unigen’s proprietary natural ingredients.  Under the agreement, Unigen granted the Estée Lauder Companies exclusive rights to groundbreaking discoveries.  Financial details of the agreement were not disclosed.

“The combination of Unigen’s commitment to developing highly effective cosmetic ingredients with the Estée Lauder Companies’ outstanding product development expertise will result in even better performing products for our consumers,” said Harvey Gedeon, Executive Vice President Global Research, Development and Product Innovation for the Estée Lauder Companies.  “We are pleased to have the exclusive rights to important Unigen discoveries—the first of which is now being used in Clinique’s exciting new products, Clinique Even Better Clinical Dark Spot Corrector and Clinique Derma White Clinical Brightening Essence.  We look forward to working with Unigen’s scientists to bring additional benefits to our other products and brands.”

“The greatest reward for scientists is to see their discovery successfully commercialized and provide meaningful benefits.  We are delighted that a company with the Estée Lauder Companies’ stature and global reach has committed to showcase our scientists’ discoveries,” said Ed Cannon, Ph.D., Unigen’s President and Chief Executive Officer. “Unigen shares a commitment to people and planet, and we are excited by the new product potential of combining with the Estée Lauder Companies’ skin biology expertise with Unigen’s natural products chemistry and biology expertise.”

For the Estée Lauder Companies the agreement formalizes an important and commercially successful collaboration with one of the leading experts in discovery and development of proprietary natural ingredients for the dietary supplement, food, cosmetics, personal care and pharmaceutical industries.  This strategic alliance combines Unigen’s innovative research and the Estee Lauder Companies’ global reach, with a commitment to the highest quality products.

About Unigen, Inc.

Unigen is a global leader in the discovery and development of proprietary natural ingredients for the dietary supplement, food, cosmetics, personal care and pharmaceutical industries.  The company has developed an extensive medicinal plant collection and a state-of-art pharmaceutical discovery process to identify novel, safe and effective botanically-based proprietary ingredients. The safety and efficacy of Unigen’s natural product ingredients are established through human clinical trials. Unlike non-natural pharmaceuticals, Unigen’s natural substances have a legacy of safe human consumption and lack the undesirable side-effects that limit the use of chemical pharmaceuticals. Unigen protects its discoveries through patents and commercializes its products through alliances with partners that possess distribution and marketing capabilities in each of Unigen’s target markets.

About The Estée Lauder Companies

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products.  The Company’s products are sold in over 150 countries and territories under the following brand names: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, M•A•C, Bobbi Brown, Tommy Hilfiger, Kiton, La Mer, Donna Karan, Aveda, Jo Malone, Bumble and bumble, Darphin, Michael Kors, American Beauty, Flirt!, GoodSkin Labs, Grassroots Research Labs, Sean John, Missoni, Daisy Fuentes, Tom Ford, Coach, Ojon and Smashbox.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish